Infant Bacterial Therapeutics
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
IBT | ST
Overview
Corporate Details
- ISIN(s):
- SE0008015242 (+3 more)
- LEI:
- 2138008KVBXCRJGP6Z26
- Country:
- Sweden
- Address:
- Bryggargatan 10, 111 21 Stockholm
- Website:
- https://ibtherapeutics.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Infant Bacterial Therapeutics (IBT) is a clinical-stage pharmaceutical company focused on developing innovative medicines for rare diseases affecting premature infants. The company's primary mission is to prevent necrotizing enterocolitis (NEC), a severe and often fatal inflammatory bowel condition. IBT's lead drug candidate, IBP-9414, is a novel live bacterial therapeutic designed to modulate the infant gut microbiome. IBP-9414, which has received Breakthrough Therapy Designation, is currently being evaluated in a pivotal Phase 3 clinical trial known as 'The Connection Study'. IBT's approach leverages its expertise in using live bacteria as active pharmaceutical substances to address significant unmet medical needs in this vulnerable patient population.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-20 08:00 |
Interim Report
|
Swedish | 586.0 KB | ||
| 2025-08-20 08:00 |
Interim Report
|
English | 565.3 KB | ||
| 2025-05-08 17:45 |
Post-Annual General Meeting Information
Annual General Meeting of Infant Bacterial Therapeutics
|
English | 41.0 KB | ||
| 2025-05-08 17:45 |
Post-Annual General Meeting Information
Årsstämma i Infant Bacterial Therapeutics
|
Swedish | 40.6 KB | ||
| 2025-05-07 14:30 |
Quarterly Report
|
Swedish | 550.1 KB | ||
| 2025-05-07 14:30 |
Quarterly Report
|
English | 549.5 KB | ||
| 2025-02-13 08:30 |
Earnings Release
|
Swedish | 577.8 KB | ||
| 2025-02-13 08:30 |
Annual Report
|
English | 571.2 KB | ||
| 2024-08-28 08:30 |
Interim Report
|
Swedish | 578.3 KB | ||
| 2024-08-28 08:30 |
Interim Report
|
English | 594.7 KB | ||
| 2024-08-15 16:44 |
Regulatory News Service
Infant Bacterial Therapeutics patent godkänt i USA
|
Swedish | 48.9 KB | ||
| 2024-08-15 16:44 |
Regulatory News Service
Patent for Infant Bacterial Therapeutics has been approved in the USA
|
English | 48.4 KB | ||
| 2024-07-08 16:40 |
Regulatory News Service
“The Connection Study” is completed
|
English | 52.7 KB | ||
| 2024-07-08 16:40 |
Regulatory News Service
“The Connection Study” är avslutad
|
Swedish | 53.8 KB | ||
| 2024-05-08 18:11 |
Post-Annual General Meeting Information
Annual General Meeting of Infant Bacterial Therapeutics
|
English | 44.2 KB |
Automate Your Workflow. Get a real-time feed of all Infant Bacterial Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Infant Bacterial Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-14 | Maria Ekdahl | Other | Buy | 500 | 17,000.00 SEK |
| 2024-02-08 | Anthon Jahreskog | Other | Buy | 839 | 79,033.80 SEK |
| 2024-02-08 | Anthon Jahreskog | Other | Buy | 161 | 15,134.00 SEK |
| 2023-06-09 | Maria Ekdahl | Other | Buy | 1,086 | 49,956.00 SEK |
| 2023-05-23 | Anders Kronström | Other | Buy | 1,329 | 56,482.50 SEK |
| 2023-05-23 | Anthon Jahreskog | Other | Buy | 851 | 36,593.00 SEK |
| 2023-05-23 | Maria Ekdahl | Other | Buy | 465 | 19,995.00 SEK |
| 2023-05-23 | Anthon Jahreskog | Other | Buy | 149 | 6,377.20 SEK |
| 2023-05-23 | Anthon Jahreskog | Other | Buy | 149 | 6,269.92 SEK |
| 2023-05-22 | Maria Ekdahl | Other | Buy | 709 | 30,487.00 SEK |
